HALS ramp is real, but margin pressure masks the momentum

On the headline, it looks like a quarter delivering on HALS momentum—and it is. Consolidated revenue hit ₹268.4 Cr, the highest ever, growing 10.5% YoY driven by HALS reaching 1,000 tons/quarter and ramping into export markets (now 50% of HALS sales). The product mix upgrade—770-grade HALS dropping from 50% to 35% of mix, higher grades rising—pushed realization from ₹440k/ton to ₹550k/ton. EBITDA margin expanded to 37% consolidated. On paper, this should have delivered outsized PAT growth. It didn't. PAT came to ₹73.3 Cr, up just 4.7% YoY.

The reason: raw material cost inflation (Middle East crude crisis), supply disruptions (2-week propylene shutdown hit legacy volumes), and partial pass-through of cost increases due to long-term customer contracts. Standalone revenue actually fell 6% YoY (from ₹216 Cr to ₹203 Cr) before HALS consolidated in. SG&A and overhead weight, despite volume leverage, dragged down the final number. Management cites this plainly in the call—not hidden—but chose to emphasize the sequential pop (QoQ +37%) over the softer YoY trend. The quarter is operationally real, but the margin squeeze is the story.

HALS is genuinely ramping. The business went from zero exports a year ago to 50% of HALS sales now; customer trials are converting to commercial shipments; product mix upgrade (higher grades) is driving ₹110/ton pricing uplift (₹440→₹550). The 1,000-ton/quarter run-rate annualizes to ₹236 Cr at current pricing, putting the ₹250–300 Cr FY-27 target within reach if volume momentum holds. Kemin (world's largest buyer of some ingredients per management) locks in a 5-year, 20–40% volume increase—no competitor can undercut that. Geneus partnership taps a new market (NOR HALS for harsh agro films, BASF-dominated) with tech transfer and co-branding upside. HQ/Catechol backward integration is now generating revenue (samples approved, ramp starting). The underlying business is scaling faster than the headline number reveals.

PAT growth of only 4.7% YoY despite EBITDA margin expansion and HALS scaleup is a red flag. It means operational headwinds—RM cost inflation, SG&A/overhead weight, only partial pass-through of cost increases—are more than offsetting volume and mix leverage. Legacy/standalone revenue fell 6% YoY; management attributes this to a 2-week propylene shutdown, not demand loss, but it still happened. PC2 commercialization slipped from September to November due to labor issues—that's one quarter of calendar slip and pushes material revenue contribution to Q1 FY-28. Geneus is unproven: ₹25 Cr new capex, new market (niche applications), BASF-dominated, ₹300–350 Cr over 3–4 years is aspirational. Supply chain confidence is low; management said plainly it's not confident disruptions won't recur ('not locked'). Kemin concentration risk: they're the largest customer; 5-year deal is upside but also locks the company into dependency if the relationship sours or demand shifts.

The stock popped +4.1% on day 1 (off the pre-result close of ₹734.05) and held +4.75% by day 3, settling around ₹768.95. This was a confident reception—the market rewarded the revenue beat (₹268.4 Cr vs. management's ₹264 Cr claim) and the visible HALS/export traction. The move held, suggesting institutional buyers stepped in to accumulate, not flip. FII ownership jumped +3.39 percentage points QoQ (from 10% to 13.39%), the strongest institutional inflow in recent quarters, signaling confidence in the HALS momentum narrative. DII pulled back -2.62pp, suggesting some domestic institutional trimming, but promoter ownership ticked up +0.33pp, a steadying signal.

Valuation context: the stock is down 28% from its all-time high of ₹1,069.80, trading at ₹768.95. It sits above its SMA20 (₹749.41) and SMA50 (₹766.97) but below SMA200 (₹818.86), in a neutral technical posture. Volume has been increasing, consistent with institutional accumulation rather than distribution. The street is clearly betting on the HALS story, but has it fully priced in the margin pressure and PC2 execution risk? The weak 4.7% YoY PAT growth suggests not yet.

YoY PAT growth in Q2 FY-27 earnings. If it accelerates to >10% as HALS ramps, RM stabilizes, and PC1 contributes, the 4.7% Q1 number was a trough. If it stays flat or slow (<5%), margin pressure is structural and will persist through FY-27, making the HALS story about volume, not profit. That single number will tell you whether this is a steady-execution story or a warning sign that leverage isn't coming as expected.